UpToDate
Official reprint from UpToDate®
www.uptodate.com ©2016 UpToDate®

Management of mucous membrane pemphigoid

Author
Kim B Yancey, MD
Section Editor
John J Zone, MD
Deputy Editor
Abena O Ofori, MD

INTRODUCTION

Mucous membrane pemphigoid (MMP) is a rare, chronic, autoimmune, subepithelial blistering and erosive disease that affects the mucosal surfaces of the mouth (gingiva, movable mucosa, tongue, and palate), eyes, nose, nasopharynx, hypopharynx, larynx, esophagus, genitals, and/or anus (picture 1A-C) [1,2]. Limited cutaneous involvement (typically localized to the head, neck, or upper trunk) also may be present. (See "Clinical features and diagnosis of bullous pemphigoid and mucous membrane pemphigoid", section on 'Mucous membrane pemphigoid'.)

MMP may cause significant morbidity due to the tissue destruction and functional limitations that result from chronic mucosal inflammation, pain, and scarring. As examples, gingival inflammation and scarring may lead to gingival recession and loss of teeth, conjunctival scarring may contribute to blindness, and laryngeal scarring may result in airway loss.

The treatment of MMP, particularly MMP involving the oral cavity, will be reviewed here. The management of ocular MMP (ocular cicatricial pemphigoid) and the clinical manifestations and diagnosis of MMP are discussed separately. (See "Ocular cicatricial pemphigoid" and "Epidemiology and pathogenesis of bullous pemphigoid and mucous membrane pemphigoid" and "Clinical features and diagnosis of bullous pemphigoid and mucous membrane pemphigoid" and "Management and prognosis of bullous pemphigoid".)

APPROACH TO TREATMENT

The primary goals of the treatment of mucous membrane pemphigoid (MMP) are to halt the progression of the disease, improve symptoms, and prevent adverse sequelae of chronic tissue inflammation and scarring [3,4]. Few high quality trials have evaluated interventions for MMP [5]. Thus, treatment is largely guided by clinical experience and small uncontrolled studies. Consistent use of the recommended measures for disease activity and treatment outcomes published in 2014 may aid in the systematic interpretation of data from future studies [6].

The approach to therapy is influenced by the following clinical factors [1]:

                   

Subscribers log in here

To continue reading this article, you must log in with your personal, hospital, or group practice subscription. For more information or to purchase a personal subscription, click below on the option that best describes you:
Literature review current through: Nov 2016. | This topic last updated: Thu Apr 07 00:00:00 GMT+00:00 2016.
The content on the UpToDate website is not intended nor recommended as a substitute for medical advice, diagnosis, or treatment. Always seek the advice of your own physician or other qualified health care professional regarding any medical questions or conditions. The use of this website is governed by the UpToDate Terms of Use ©2016 UpToDate, Inc.
References
Top
  1. Chan LS, Ahmed AR, Anhalt GJ, et al. The first international consensus on mucous membrane pemphigoid: definition, diagnostic criteria, pathogenic factors, medical treatment, and prognostic indicators. Arch Dermatol 2002; 138:370.
  2. Fleming TE, Korman NJ. Cicatricial pemphigoid. J Am Acad Dermatol 2000; 43:571.
  3. Kirtschig G, Murrell D, Wojnarowska F, Khumalo N. Interventions for mucous membrane pemphigoid/cicatricial pemphigoid and epidermolysis bullosa acquisita: a systematic literature review. Arch Dermatol 2002; 138:380.
  4. Lazarova Z, Yancey KB. Cicatricial pemphigoid: immunopathogenesis and treatment. Dermatologic Therapy 2002; 15:382.
  5. Kirtschig G, Murrell D, Wojnarowska F, Khumalo N. Interventions for mucous membrane pemphigoid and epidermolysis bullosa acquisita. Cochrane Database Syst Rev 2003; :CD004056.
  6. Murrell DF, Marinovic B, Caux F, et al. Definitions and outcome measures for mucous membrane pemphigoid: Recommendations of an international panel of experts. J Am Acad Dermatol 2014.
  7. Ahmed AR, Hombal SM. Cicatricial pemphigoid. Int J Dermatol 1986; 25:90.
  8. Lee MS, Wakefield PE, Konzelman JL Jr, James WD. Oral insertable prosthetic device as an aid in treating oral ulcers. Arch Dermatol 1991; 127:479.
  9. Gonzalez-Moles MA, Ruiz-Avila I, Rodriguez-Archilla A, et al. Treatment of severe erosive gingival lesions by topical application of clobetasol propionate in custom trays. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 2003; 95:688.
  10. Assmann T, Becker J, Ruzicka T, Megahed M. Topical tacrolimus for oral cicatricial pemphigoid. Clin Exp Dermatol 2004; 29:674.
  11. Lee HY, Blazek C, Beltraminelli H, Borradori L. Oral mucous membrane pemphigoid: complete response to topical tacrolimus. Acta Derm Venereol 2011; 91:604.
  12. Suresh L, Martinez Calixto LE, Radfar L. Successful treatment of mucous membrane pemphigoid with tacrolimus. Spec Care Dentist 2006; 26:66.
  13. http://www.fda.gov/Drugs/DrugSafety/PostmarketDrugSafetyInformationforPatientsandProviders/ucm051760.htm (Accessed on November 01, 2012).
  14. Ahmed AR, Kurgis BS, Rogers RS 3rd. Cicatricial pemphigoid. J Am Acad Dermatol 1991; 24:987.
  15. Gürcan HM, Ahmed AR. Efficacy of dapsone in the treatment of pemphigus and pemphigoid: analysis of current data. Am J Clin Dermatol 2009; 10:383.
  16. Rogers RS 3rd, Seehafer JR, Perry HO. Treatment of cicatricial (benign mucous membrane) pemphigoid with dapsone. J Am Acad Dermatol 1982; 6:215.
  17. Ciarrocca KN, Greenberg MS. A retrospective study of the management of oral mucous membrane pemphigoid with dapsone. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 1999; 88:159.
  18. Arash A, Shirin L. The management of oral mucous membrane pemphigoid with dapsone and topical corticosteroid. J Oral Pathol Med 2008; 37:341.
  19. Matthews RW, Pinkney RC, Scully C. The management of intransigent desquamative gingivitis with Dapsone. Ann Dent 1989; 48:41.
  20. Rogers RS 3rd, Mehregan DA. Dapsone therapy of cicatricial pemphigoid. Semin Dermatol 1988; 7:201.
  21. Hegarty AM, Ormond M, Sweeney M, Hodgson T. Dapsone efficacy and adverse events in the management of mucous membrane pemphigoid. Eur J Dermatol 2010; 20:223.
  22. Foster CS. Cicatricial pemphigoid. Trans Am Ophthalmol Soc 1986; 84:527.
  23. Tauber J, Sainz de la Maza M, Foster CS. Systemic chemotherapy for ocular cicatricial pemphigoid. Cornea 1991; 10:185.
  24. Hall RP, Mickle CP. Dapsone. In: Comprehensive Dermatologic Drug Therapy, 2nd ed, Wolverton SE (Ed), Elsevier Inc., Philadelphia 2007. p.239.
  25. Kourosh AS, Yancey KB. Therapeutic approaches to patients with mucous membrane pemphigoid. Dermatol Clin 2011; 29:637.
  26. Saw VP, Dart JK, Rauz S, et al. Immunosuppressive therapy for ocular mucous membrane pemphigoid strategies and outcomes. Ophthalmology 2008; 115:253.
  27. Megahed M, Schmiedeberg S, Becker J, Ruzicka T. Treatment of cicatricial pemphigoid with mycophenolate mofetil as a steroid-sparing agent. J Am Acad Dermatol 2001; 45:256.
  28. Lugović L, Buljan M, Situm M, et al. Unrecognized cicatricial pemphigoid with oral manifestations and ocular complications. A case report. Acta Dermatovenerol Croat 2007; 15:236.
  29. Korman NJ. Update on the use of azathioprine in the management of pemphigus and bullous pemphigoid. Med Surg Dermatol 1996; 3:209.
  30. Korman NJ. Update on the use of cyclophosphamide in the management of pemphigus, bullous pemphigoid, and cicatricial pemphigoid. Med Surg Dermatol 1998; 5:1.
  31. Doycheva D, Deuter C, Blumenstock G, et al. Long-term results of therapy with mycophenolate mofetil in ocular mucous membrane pemphigoid. Ocul Immunol Inflamm 2011; 19:431.
  32. Nottage JM, Hammersmith KM, Murchison AP, et al. Treatment of mucous membrane pemphigoid with mycophenolate mofetil. Cornea 2013; 32:810.
  33. Staines K, Hampton PJ. Treatment of mucous membrane pemphigoid with the combination of mycophenolate mofetil, dapsone, and prednisolone: a case series. Oral Surg Oral Med Oral Pathol Oral Radiol 2012; 114:e49.
  34. Segura S, Iranzo P, Martínez-de Pablo I, et al. High-dose intravenous immunoglobulins for the treatment of autoimmune mucocutaneous blistering diseases: evaluation of its use in 19 cases. J Am Acad Dermatol 2007; 56:960.
  35. Foster CS, Ahmed AR. Intravenous immunoglobulin therapy for ocular cicatricial pemphigoid: a preliminary study. Ophthalmology 1999; 106:2136.
  36. Ahmed AR, Dahl MV. Consensus statement on the use of intravenous immunoglobulin therapy in the treatment of autoimmune mucocutaneous blistering diseases. Arch Dermatol 2003; 139:1051.
  37. Sami N, Letko E, Androudi S, et al. Intravenous immunoglobulin therapy in patients with ocular-cicatricial pemphigoid: a long-term follow-up. Ophthalmology 2004; 111:1380.
  38. Letko E, Miserocchi E, Daoud YJ, et al. A nonrandomized comparison of the clinical outcome of ocular involvement in patients with mucous membrane (cicatricial) pemphigoid between conventional immunosuppressive and intravenous immunoglobulin therapies. Clin Immunol 2004; 111:303.
  39. Ahmed AR, Colón JE. Comparison between intravenous immunoglobulin and conventional immunosuppressive therapy regimens in patients with severe oral pemphigoid: effects on disease progression in patients nonresponsive to dapsone therapy. Arch Dermatol 2001; 137:1181.
  40. Sami N, Bhol KC, Razzaque Ahmed A. Intravenous immunoglobulin therapy in patients with multiple mucosal involvement in mucous membrane pemphigoid. Clin Immunol 2002; 102:59.
  41. Foster CS, Chang PY, Ahmed AR. Combination of rituximab and intravenous immunoglobulin for recalcitrant ocular cicatricial pemphigoid: a preliminary report. Ophthalmology 2010; 117:861.
  42. Ross AH, Jaycock P, Cook SD, et al. The use of rituximab in refractory mucous membrane pemphigoid with severe ocular involvement. Br J Ophthalmol 2009; 93:421.
  43. Le Roux-Villet C, Prost-Squarcioni C, Alexandre M, et al. Rituximab for patients with refractory mucous membrane pemphigoid. Arch Dermatol 2011; 147:843.
  44. Kasperkiewicz M, Shimanovich I, Ludwig RJ, et al. Rituximab for treatment-refractory pemphigus and pemphigoid: a case series of 17 patients. J Am Acad Dermatol 2011; 65:552.
  45. Shetty S, Ahmed AR. Critical analysis of the use of rituximab in mucous membrane pemphigoid: a review of the literature. J Am Acad Dermatol 2013; 68:499.
  46. Heelan K, Walsh S, Shear NH. Treatment of mucous membrane pemphigoid with rituximab. J Am Acad Dermatol 2013; 69:310.
  47. Maley A, Warren M, Haberman I, et al. Rituximab combined with conventional therapy versus conventional therapy alone for the treatment of mucous membrane pemphigoid (MMP). J Am Acad Dermatol 2016; 74:835.
  48. Reiche L, Wojnarowska F, Mallon E. Combination therapy with nicotinamide and tetracyclines for cicatricial pemphigoid: further support for its efficacy. Clin Exp Dermatol 1998; 23:254.
  49. Carrozzo M, Arduino P, Bertolusso G, et al. Systemic minocycline as a therapeutic option in predominantly oral mucous membrane pemphigoid: a cautionary report. Int J Oral Maxillofac Surg 2009; 38:1071.
  50. Carrozzo M, Arduino PG, Baldovino S, et al. Minocycline in combination with mycophenolate mofetil in oral mucous membrane pemphigoid. Eur J Dermatol 2008; 18:198.
  51. Duong DJ, Moxley RT 3rd, Kellman RM, et al. Thalidomide therapy for cicatricial pemphigoid. J Am Acad Dermatol 2002; 47:S193.